Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22442230 | 0.85 | PARP1 (0.42) | PARP1PIM1PIM2 | |
| SCHEMBL22442223 | 0.83 | PARP1 (0.46) | PARP1ALOX5PARP10PARP11 | |
| SCHEMBL22442238 | 0.79 | PARP1 (0.40) | PARP1 | |
| SCHEMBL22367404 | 0.79 | ALOX5 (0.43) | PARP1ALOX5HTR2AHTR2CHTR2B | |
| SCHEMBL22367322 | 0.78 | PARP10 (0.40) | PARP1PARP10PARP11HTR2AHTR2C | |
| SCHEMBL20571883 | 0.78 | HTR2A (0.37) | PARP1ALOX5HTR2AHTR2CHTR2B | |
| SCHEMBL22367368 | 0.76 | CACNA2D1 (0.40) | PARP1 | |
| SCHEMBL27309340 | 0.75 | PARP1 (0.37) | PARP1ALOX5PIM1PIM2 | |
| SCHEMBL22367242 | 0.75 | PARP1 (0.46) | PARP1PARP10PARP11 | |
| SCHEMBL19564595 | 0.72 | PRKD1 (0.40) | PARP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| EP-3700890-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNB2, CACNA1G | PARP1 2628/4885ALOX5 1027/4885PARP10 2523/4885 |
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | PARP1 2206/4885ALOX5 1107/4885PARP10 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.